Which Polivy trials used the strongest efficacy endpoints?
Polivy (polatuzumab vedotin) efficacy in clinical trials is mainly shown through objective response rate (ORR), complete response (CR), and duration of response (DoR) in combination regimens, especially in settings where patients previously received treatment.
In the pivotal Phase 2 study (GO29365), Polivy was tested with bendamustine and a rituximab backbone (the B-R component varies by arm), and efficacy was evaluated as responses among patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study reported response rates and how long those responses lasted, using endpoints typical for this disease setting [1][2].
A key efficacy dataset also comes from a Phase 3 randomized trial (often referenced alongside the pivotal study program) in relapsed or refractory DLBCL, where Polivy plus standard chemotherapy improved response outcomes compared with control regimens [3]. Across these trial programs, the way “efficacy” is demonstrated is not through survival alone in every report, but through measured tumor shrinkage and durability of response.
How does Polivy’s efficacy show up in ORR, CR, and DoR?
Across the Polivy clinical trial program in relapsed/refractory DLBCL, efficacy is demonstrated by:
- ORR: the proportion of patients whose tumors shrink to a predefined level.
- CR: the proportion of patients who achieve complete disappearance of detectable disease by trial criteria.
- DoR: how long responses persist before disease progression.
These are the core efficacy measures used in the main DLBCL trials in which Polivy was combined with chemotherapy backbones and assessed with standardized lymphoma response criteria [1][2][3].
What patient groups did the efficacy data come from?
The trials that demonstrate Polivy’s efficacy were conducted in relapsed or refractory DLBCL populations, including patients who had already received prior therapy. In that context, response rate and durability are used to show how well Polivy-based combinations control disease after relapse [1][2].
How do combination regimens factor into efficacy?
Polivy’s efficacy results come from its use as part of combination treatment rather than as monotherapy in the pivotal DLBCL evidence base. In trials, Polivy was paired with chemotherapy (including bendamustine) and rituximab-based components, and the measured ORR/CR/DoR reflect the performance of the overall regimen containing Polivy [1][2].
What comparisons do the trials make to show Polivy works?
The strongest efficacy demonstrations come from studies that compare Polivy-containing combinations against a control regimen lacking Polivy, typically standard chemotherapy with or without the same biologic partner (for example, rituximab). Those comparisons focus on whether the Polivy regimen produces better response outcomes and whether responses last longer [3].
How do you interpret “efficacy” if survival outcomes aren’t the headline?
In the major Polivy DLBCL trial reports, efficacy is often presented first through response and duration endpoints (ORR, CR, and DoR). This matters because in relapsed/refractory lymphoma, response quality and durability are clinically meaningful and are used to support benefit even when longer-term survival endpoints mature later. The trial publications use these endpoints as the primary demonstration of anti-lymphoma effect [1][2][3].
---
Sources
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761084s025lbl.pdf
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384657/
- https://www.cancer.gov/publications/dictionaries/cancer-drug/registry/polatuzumab-vedotin-pii/protocols